Italy · Delayed Price · Currency is EUR Svas Biosana Statistics
Total Valuation
Svas Biosana has a market cap or net worth of EUR 52.07 million. The enterprise value is 97.00 million.
| Market Cap | 52.07M |
| Enterprise Value | 97.00M |
Important Dates
The next estimated earnings date is Tuesday, December 23, 2025.
| Earnings Date | Dec 23, 2025 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Svas Biosana has 5.31 million shares outstanding.
| Current Share Class | 5.31M |
| Shares Outstanding | 5.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.31% |
| Owned by Institutions (%) | 7.59% |
| Float | 1.55M |
Valuation Ratios
The trailing PE ratio is 7.72 and the forward PE ratio is 7.00.
| PE Ratio | 7.72 |
| Forward PE | 7.00 |
| PS Ratio | 0.39 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.11, with an EV/FCF ratio of -22.38.
| EV / Earnings | 14.38 |
| EV / Sales | 0.72 |
| EV / EBITDA | 6.11 |
| EV / EBIT | 8.79 |
| EV / FCF | -22.38 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.79 |
| Quick Ratio | 1.29 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 4.60 |
| Debt / FCF | -16.84 |
| Interest Coverage | 2.57 |
Financial Efficiency
Return on equity (ROE) is 10.92% and return on invested capital (ROIC) is 5.30%.
| Return on Equity (ROE) | 10.92% |
| Return on Assets (ROA) | 4.08% |
| Return on Invested Capital (ROIC) | 5.30% |
| Return on Capital Employed (ROCE) | 10.34% |
| Revenue Per Employee | 385,579 |
| Profits Per Employee | 19,267 |
| Employee Count | 327 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 2.88 |
Taxes
In the past 12 months, Svas Biosana has paid 2.37 million in taxes.
| Income Tax | 2.37M |
| Effective Tax Rate | 26.02% |
Stock Price Statistics
The stock price has increased by +33.33% in the last 52 weeks. The beta is 0.97, so Svas Biosana's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +33.33% |
| 50-Day Moving Average | 8.49 |
| 200-Day Moving Average | 7.94 |
| Relative Strength Index (RSI) | 78.88 |
| Average Volume (20 Days) | 17,220 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Svas Biosana had revenue of EUR 134.95 million and earned 6.74 million in profits.
| Revenue | 134.95M |
| Gross Profit | 37.09M |
| Operating Income | 11.03M |
| Pretax Income | 9.12M |
| Net Income | 6.74M |
| EBITDA | 15.87M |
| EBIT | 11.03M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 28.09 million in cash and 73.00 million in debt, giving a net cash position of -44.92 million or -8.45 per share.
| Cash & Cash Equivalents | 28.09M |
| Total Debt | 73.00M |
| Net Cash | -44.92M |
| Net Cash Per Share | -8.45 |
| Equity (Book Value) | 64.64M |
| Book Value Per Share | n/a |
| Working Capital | 58.16M |
Cash Flow
In the last 12 months, operating cash flow was -552,693 and capital expenditures -3.78 million, giving a free cash flow of -4.33 million.
| Operating Cash Flow | -552,693 |
| Capital Expenditures | -3.78M |
| Free Cash Flow | -4.33M |
| FCF Per Share | -0.82 |
Margins
Gross margin is 27.48%, with operating and profit margins of 8.17% and 5.00%.
| Gross Margin | 27.48% |
| Operating Margin | 8.17% |
| Pretax Margin | 6.76% |
| Profit Margin | 5.00% |
| EBITDA Margin | 11.76% |
| EBIT Margin | 8.17% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 2.55%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 2.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 19.64% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.55% |
| Earnings Yield | 12.95% |
| FCF Yield | -8.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Svas Biosana has an Altman Z-Score of 1.76 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.76 |
| Piotroski F-Score | 3 |